STOCK TITAN

Scholar Rock Holding Corporation - $SRRK STOCK NEWS

Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: $SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scholar Rock Holding Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scholar Rock Holding Corporation's position in the market.

Rhea-AI Summary
Scholar Rock to host conference call to discuss Q3 2023 financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences earnings
-
Rhea-AI Summary
Scholar Rock to present data from the DRAGON trial at the Society for Immunotherapy of Cancer Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences clinical trial
-
Rhea-AI Summary
Scholar Rock announces the closing of its underwritten public offering, raising approximately $97.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
Rhea-AI Summary
Scholar Rock Holding Corporation announces pricing of upsized public offering of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags
-
Rhea-AI Summary
Scholar Rock Holding Corporation announces underwritten public offering of $75.0 million of its common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags
-
Rhea-AI Summary
Scholar Rock plans to expand into cardiometabolic disorders with the advancement of SRK-439, a myostatin inhibitor for the treatment of obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.66%
Tags
none
Rhea-AI Summary
Scholar Rock completes enrollment of SAPPHIRE Phase 3 trial for apitegromab in SMA patients. Plans to present 36-month data from TOPAZ trial at World Muscle Society Congress. Positive outlook for potential benefit beyond SMN therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.74%
Tags
-
Rhea-AI Summary
Scholar Rock grants inducement equity awards to newly hired employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Scholar Rock grants inducement equity awards to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.33%
Tags
Scholar Rock Holding Corporation

Nasdaq:SRRK

SRRK Rankings

SRRK Stock Data

996.13M
48.17M
2.25%
106.94%
16.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About SRRK

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s